These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38693765)

  • 21. CAR T-Cell Therapy in Autoimmune Disease.
    Howard JF; Vu T; Mozaffar T
    N Engl J Med; 2024 May; 390(17):1629-1631. PubMed ID: 38692299
    [No Abstract]   [Full Text] [Related]  

  • 22. CAR-T cell therapy in paediatric acute lymphoblastic leukaemia - past, present and future.
    Rogosic S; Ghorashian S
    Br J Haematol; 2020 Nov; 191(4):617-626. PubMed ID: 33190266
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Autoimmunity as a target for chimeric immune receptor therapy: A new vision to therapeutic potential.
    Haddadi MH; Hajizadeh-Saffar E; Khosravi-Maharlooei M; Basiri M; Negahdari B; Baharvand H
    Blood Rev; 2020 May; 41():100645. PubMed ID: 31813654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advancements and challenges in CAR T cell therapy in autoimmune diseases.
    Schett G; Müller F; Taubmann J; Mackensen A; Wang W; Furie RA; Gold R; Haghikia A; Merkel PA; Caricchio R; D'Agostino MA; Locatelli F; June CH; Mougiakakos D
    Nat Rev Rheumatol; 2024 Sep; 20(9):531-544. PubMed ID: 39107407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment.
    Yan Z; Zhang H; Cao J; Zhang C; Liu H; Huang H; Cheng H; Qiao J; Wang Y; Wang Y; Gao L; Shi M; Sang W; Zhu F; Li D; Sun H; Wu Q; Qi Y; Li H; Wang X; Li Z; Liu H; Zheng J; Qian W; Zhang X; Xu K
    Front Immunol; 2021; 12():611366. PubMed ID: 33708205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
    Zhou Z; Zhang G; Xu Y; Yang S; Wang J; Li Z; Peng F; Lu Q
    Cancer Lett; 2024 Aug; 597():217083. PubMed ID: 38925363
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CAR T-cell expansion: harmful or helpful?
    Lionel AC; Neelapu SS
    Blood Adv; 2024 Jun; 8(12):3311-3313. PubMed ID: 38916899
    [No Abstract]   [Full Text] [Related]  

  • 30. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chimeric Antigen Receptor-Engineered T Cell Therapy for the Management of Patients with Metastatic Prostate Cancer: A Comprehensive Review.
    Yu YD; Kim TJ
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33440664
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CAR-T Cell Therapy.
    Ahmad A
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chimeric antigen receptor (CAR)-T-cell therapy in non-small-cell lung cancer (NSCLC): current status and future perspectives.
    Qu J; Mei Q; Chen L; Zhou J
    Cancer Immunol Immunother; 2021 Mar; 70(3):619-631. PubMed ID: 33025047
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
    Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
    Front Immunol; 2018; 9():1717. PubMed ID: 30108584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?
    Sadeqi Nezhad M; Seifalian A; Bagheri N; Yaghoubi S; Karimi MH; Adbollahpour-Alitappeh M
    Front Immunol; 2020; 11():603237. PubMed ID: 33324420
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy Deriving from CAR-T Cell Treatment in Autoimmune Diseases.
    Chen Y; Sun J; Liu H; Yin G; Xie Q
    J Immunol Res; 2019; 2019():5727516. PubMed ID: 32083141
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dawn of CAR-T cell therapy in autoimmune diseases.
    Liu Y; Dong M; Chu Y; Zhou L; You Y; Pang X; Yang S; Zhang L; Chen L; Zhu L; Xiao J; Wang W; Qin C; Tian D
    Chin Med J (Engl); 2024 May; 137(10):1140-1150. PubMed ID: 38613216
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Application of CAR-T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment.
    Adabi N; Pordel S; Rezaee MA; Shobeiri FS; Shobeiri SS
    J Gene Med; 2023 May; 25(5):e3484. PubMed ID: 36781390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen receptor T-cell therapy for autoimmune diseases of the central nervous system: a systematic literature review.
    Konitsioti AM; Prüss H; Laurent S; Fink GR; Heesen C; Warnke C
    J Neurol; 2024 Oct; 271(10):6526-6542. PubMed ID: 39276207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.